Immunotherapy for Advanced Melanoma
作者： Lei Fang , Anke S. Lonsdorf , Sam T. Hwang
DOI: 10.1038/JID.2008.101
关键词:
摘要: Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with high dose IL-2. Herein, strategies boost patient antitumor immunity through vaccination, treatment agents that augment host immunity, and adoptive cell transfer will be discussed. The two have yielded only limited clinical success, but therapy, particularly following a lymphodepleting, preconditioning regimen resulted in objective response rates approaching 50%. For number of reasons, lymphodepletion appears critical maintenance circulating T cells transfer. Balancing efficacy, autoimmunity, reconstitution functioning immune system remain challenging potentially life-threatening issues.
nature.com
core.ac.uk
elsevier.com
jidonline.org参考文章(98)
Michael Yellin, Alan Korman, Tibor Keler, Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Current opinion in investigational drugs. ,vol. 6, pp. 582- 591 ,(2005)
Nancy R. Porzio, Yolaine Farcet, Robert S. Bart, Jan T. Vilcek, Alfred W. Kopf, Edward H. Cheng, Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Research. ,vol. 40, pp. 614- 619 ,(1980)
Peter P. Lee, Cassian Yee, Peter A. Savage, Lawrence Fong, Dirk Brockstedt, Jeffrey S. Weber, Denise Johnson, Susan Swetter, John Thompson, Philip D. Greenberg, Mario Roederer, Mark M. Davis, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients Nature Medicine. ,vol. 5, pp. 677- 685 ,(1999) , 10.1038/9525
Armen B. Shanafelt, Yue Lin, Marie-Claude Shanafelt, Carla P. Forte, Nathalie Dubois-Stringfellow, Christopher Carter, Jacqueline A. Gibbons, Shu-lan Cheng, Katherine A. Delaria, Richard Fleischer, Jeffrey M. Greve, Robert Gundel, Kathleen Harris, Ruth Kelly, Beth Koh, Ying Li, Lori Lantz, Polly Mak, Lauri Neyer, Mary Jane Plym, Steve Roczniak, Daniel Serban, John Thrift, Linda Tsuchiyama, Monte Wetzel, Mel Wong, Alya Zolotorev, A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo. Nature Biotechnology. ,vol. 18, pp. 1197- 1202 ,(2000) , 10.1038/81199
A Fefer, M A Cheever, P D Greenberg, Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. Journal of Immunology. ,vol. 125, pp. 711- 714 ,(1980)
Daniel J. Powell, Mark E. Dudley, Katherine A. Hogan, John R. Wunderlich, Steven A. Rosenberg, Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Journal of Immunology. ,vol. 177, pp. 6527- 6539 ,(2006) , 10.4049/JIMMUNOL.177.9.6527
Vijay Shankaran, Hiroaki Ikeda, Allen T. Bruce, J. Michael White, Paul E. Swanson, Lloyd J. Old, Robert D. Schreiber, IFNγ, and lymphocytes prevent primary tumour development and shape tumour immunogenicity Nature. ,vol. 410, pp. 1107- 1111 ,(2001) , 10.1038/35074122
J M Kirkwood, M H Strawderman, M S Ernstoff, T J Smith, E C Borden, R H Blum, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Journal of Clinical Oncology. ,vol. 14, pp. 7- 17 ,(1996) , 10.1200/JCO.1996.14.1.7
Steven A. Rosenberg, James C. Yang, Douglas J. Schwartzentruber, Patrick Hwu, Francesco M. Marincola, Suzanne L. Topalian, Claudia A. Seipp, Jan H. Einhorn, Donald E. White, Seth M. Steinberg, Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b Journal of Clinical Oncology. ,vol. 17, pp. 968- 975 ,(1999) , 10.1200/JCO.1999.17.3.968
John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum, High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 Journal of Clinical Oncology. ,vol. 18, pp. 2444- 2458 ,(2000) , 10.1200/JCO.2000.18.12.2444